The global airway disease treatment market demand is projected to amass a revenue of around US$ 3,495.3 million by 2032, up from US$ 1,996.1 million in 2022 moving forward with a CAGR of 5.2% during the forecast period. LABA-ICS, LAMA-ICS, triple treatment, and other related drugs are among the pharmaceuticals used in combination therapy for COPD....